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Abstract
Background: Long-term treatment with antibiotics containing pivalic acid may decrease serum carnitine
concentration and can sometimes be associated with severe hypoglycemia and encephalopathy in infants.
Little has been reported, however, on severe hypocarnitinemia induced by acute administration in older
children.
Case presentation: We describe a 6-year-old Japanese girl with Fukuyama-type congenital muscular dystrophy who
lost consciousness after 3 days of treatment with an antibiotic containing pivalic acid (cefditoren pivoxil). Investigations
at the onset of unconsciousness revealed hypoglycemia (free plasma glucose concentration: 31 mg/dL) and
hypocarnitinemia (serum free carnitine concentration: 6.2 μmol/L). Intravenous administration of glucose rapidly improved
her symptoms without any complications. Serum free carnitine concentration was 29.0 μmol/L immediately
prior to the initiation of cefditoren pivoxil. Computed tomography scanning showed severe peripheral skeletal
muscle atrophy, indicating the likelihood of decreased carnitine stores in skeletal muscle.
Conclusions: Although serum carnitine concentration can appear deceptively normal, skeletal muscle carnitine
stores can be reduced in patients with severe muscular atrophy. Even a short course of a pivalate-containing
antibiotic can lead to life-threatening hypocarnitinemia in older children with severe muscular dystrophy.
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Background
Carnitine, a water-soluble quaternary amine, is respon-
sible for the intracellular transport of long-chain fatty
acids into mitochondria, facilitating fatty acid oxidation.
Severe carnitine deficiency impairs β-oxidation, and
thereby the ability to produce glucose, which may result
in hypoglycemia. Although most patients with carnitine
deficiency are asymptomatic, it can cause muscle weak-
ness, hypotonia, nausea and vomiting, fatigue, recurrent
infection, failure to thrive, poor appetite, poor concen-
tration, apathy, and headaches. Furthermore, carnitine
deficiency can occasionally cause severe and life-
threatening complications, including hypoglycemic
encephalopathy and dilated cardiomyopathy [1, 2].
Carnitine deficiency may be classified as primary or
secondary; the primary form is associated with genetic-
ally determined metabolic errors whereas the secondary
form is associated with acquired diseases or iatrogenic
factors such as drug administration. Recent studies have
reported that severe secondary carnitine deficiency
induced by long-term administration of pivalate-
containing antibiotics, particularly for more than 14 days,
causes hypoketotic hypoglycemia and acute encephalop-
athy in infants [3–6]. However, there have been few
reports to date of carnitine deficiency provoked by
short-term antibiotics in older children. Here, we report
the case of a 6-year-old girl with Fukuyama-type con-
genital muscular dystrophy (FCMD) who developed
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severe hypoglycemia caused by carnitine deficiency after
a 3-day oral course of cefditoren pivoxil (CDTR-PI), an
antibiotic containing pivalic acid.
Case presentation
A 6-year-old Japanese girl with FCMD was admitted to
our hospital with sudden-onset impaired consciousness.
She had been diagnosed with FCMD by genetic testing
at 9 months of age, having a homo-retrotransposon in-
sertional mutation of the fukutin gene. Her height was
108 cm (−1.0 SD) and weight was 13.0 kg (−2.0 SD). She
was able to sit but not stand, and could eat only a soft
diet. Her Gross Motor Function Classification System
score was level five [7]. She had previously been admit-
ted to hospital for treatment of acute pharyngitis, for
which she was prescribed CDTR-PI (8.5 mg/kg/day
orally). During this time, she could consume half of her
usual calorific intake without weight loss or dehydration.
After 3 days of treatment, her level of consciousness
declined. On physical examination, her Glasgow Coma
Scale score was 9 out of 15 (E3V2M4), core temperature
was 36.6 °C, blood pressure was 108/68 mmHg, and
heart rate was 130 beats/min. Laboratory investigations
revealed a serum creatine kinase concentration of
588 IU/L and hypoglycemia (free plasma glucose con-
centration of 31 mg/dL). Hepatic and renal function,
serum electrolyte and ammonia concentrations, and
acid-base balance were all within the normal range, but
serum free carnitine concentration was markedly
reduced (6.2 μmol/L) (Table 1).
We diagnosed the patient with hypoglycemia originat-
ing from a carnitine deficiency induced by CDTR-PI, as
the serum free carnitine concentration was 29.0 μmol/L
when measured retrospectively in a sample taken 3 days
before CDTR-PI treatment was initiated. The patient
was immediately administered intravenous glucose and
her level of consciousness rapidly improved without any
complications. We discontinued CDTR-PI treatment
and initiated L-carnitine supplementation. One month
later, the patient’s serum free carnitine concentration lay
within the normal range with no relapse of symptoms,
hypoglycemia, or side effects reported (Fig. 1a).
Computed tomography (CT) scanning undertaken to
evaluate skeletal muscle volume showed severe atrophy
of the peripheral muscles compared with an age-
matched healthy child who had undergone CT to inves-
tigate left leg pain (Fig. 1b). We also calculated the renal
reabsorption rate of free carnitine (RRFC) using the
following equation: RRFC (%) = 1 − (urine free carni-
tine × serum creatinine)/(serum free carnitine × urine
creatinine). An RRFC of 98% (normal value: >95%) indi-
cated that renal carnitine malabsorption was not respon-
sible for the patient’s episode of hypocarnitinemia [8].
Serum creatinine concentration was <0.1 mg/dL in this
case; therefore, we substituted 0.1 mg/dL and considered
that the true RRFC value must have been above 98%.
Discussion
Our patient suffered severe carnitine deficiency induced
by 3-day oral administration of CDTR-PI. Pivalic acid is
released as a result of the metabolism of the prodrug
CDTR-PI, and combines with serum free carnitine to
form pivaloylcarnitine, which is excreted by the kidneys.
Consequently, long-term treatment with an antibiotic
containing pivalic acid may provoke hypocarnitinemia
[3–6, 9], especially in patients at risk of carnitine defi-
ciency such as those with inherited causes of carni-
tine metabolism, severe epilepsy, renal disorders or
severe neurologic disability, infants less than 2 years
old, and patients fed parenterally or taking multiple
antiepileptic drugs [10, 11]. However, a case has been
reported of a 1-year-old Japanese patient with
hypoglycemia associated with hypocarnitinemia in-
duced by 2 days of cefcapene pivoxil treatment [12].
Additionally, Ito et al. reported that treatment with
cefteram pivoxil significantly decreased the level of
serum free carnitine in both children and adults, even





Biochemistry Blood gas (vein)
WBC 1.8 × 103/μl TP 7.1 g/dl pH 7.428
RBC 3.5 × 106/μl AST 65 U/l pO2 46.4 mmHg
Hb 12.9 g/dl ALT 38 U/l, pCO2 39.9 mmHg
Plt 38.9 × 105/μl Na 135 mEq/l HCO3- 26.3 mmol/l
K 4.2 mEq/l BE 1.8 mmol/l







Serum carnitine Serum carnitine (just 3 days before
cefditoren pivixil was started)
Total Carnitine 14.1 μmol/l Total Carnitine 33.7 μmol/l
Free Carnitine 6.2 μmol/l Free Carnitine 29.0 μmol/l
Acyl Carnitine 4.7 μmol/l Acyl Carnitine 7.9 μmol/l
Chest X-ray Echocardiographic
study
Cardiothoracic ratio 50% IVC diameter 11 mm
Lungs normal Caval/Ao ratio 0.9 (normal value:
0.8–1.0)
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in short-term therapy, and advised that carnitine sup-
plementation may be necessary for patients who are
taking these antibiotics, particularly those vulnerable
to carnitine deficiency [13]. Although our patient was
an older child who could usually receive adequate
calories orally (1200 kcal/day, appropriate for her
body weight and activity level), she did not receive
enough to eat for 3 days (about half of her usual
calorific intake) after antibiotic treatment was initiated
because of her acute pharyngitis.
We judge, however, that even if our patient’s diet had
been marginally deficient in carnitine, her most import-
ant risk factor for carnitine deficiency was severe muscu-
lar dystrophy. Large quantities of carnitine can be stored
in skeletal muscle; in a healthy patient, the proportion
stored in skeletal muscle exceeds 95% [1]. Consequently,
severe muscle atrophy such as that seen in patients with
Duchenne or Becker muscular dystrophy [14, 15] re-
duces the capacity to store carnitine and replenish
serum free carnitine when it is suddenly depleted, even
when the renal reabsorption of carnitine is normal. As
far as we are aware, there have been no previous reports
of carnitine deficiency in FCMD, but our patient’s skel-
etal muscle volume was markedly lower than that of a
healthy child. We suggest that the patient’s reduced
muscle bulk would have further predisposed her to
hypoglycemia, which was likely to the result of a lack of
glycogen and glycogenic amino acid storage in skeletal
muscle as well as β-oxidation impairment. Fever would
also have induced a hypercatabolic state that would have
markedly elevated glucose consumption.
We did not measure blood and urine ketone bodies, a
diagnostic limitation for hypoketotic hypoglycemia in
this patient, because we imitated prompt emergency
treatment for severe hypoglycemia to prevent permanent
central nervous system damage. However, the normal ven-
ous blood gas test results arguably preclude the possibility
of ketotic hypoglycemia. Early diagnosis and rapid, appro-
priate treatment for severe hypoglycemia resolved our
patient’s symptoms without any complications.
The rapid fall in serum free carnitine from 29.0 μmol/
L to 6.2 μmol/L observed in this girl with FCMD after
just 3 days of treatment with CDTR-PI underlines the
speed at which potentially life-threatening symptoms
can develop in patients at risk of carnitine deficiency. It
is important to note that pivalate antibiotics are not the
only type of antibiotic that can influence serum free car-
nitine; β-lactam antibiotics are reported to competitively
block the binding of organic cation/carnitine trans-
porter 2 (OCTN2) and inhibit reabsorption in the
kidney [16, 17]. As far as we are aware, however,
there have been no reports of β-lactam antibiotics causing
adverse events such as those seen in this case.
Conclusions
This case shows that even short-term administration of
antibiotics containing pivalic acid in older children with
severe musculoskeletal disorders requires careful moni-
toring for carnitine deficiency to avoid serious adverse
effects. Alternative antibiotics should therefore be
administered to children at risk. Supplementation with
L-carnitine is recommended so that complications can
be avoided if alternative antibiotics cannot be identified.
Abbreviations
CDTR-PI: Cefditoren pivoxil; CT: Computed tomography; FCMD: Fukuyama-
type congenital muscular dystrophy; OCTN2: Organic cation/carnitine
transporter 2; RRFC: Renal reabsorption rate of free carnitine
Fig. 1 Clinical course and computed tomography (CT) scanning of the central part of the femoral muscles. a Clinical course of the patient from
the onset of coma 3 days after initiation of treatment with cefditoren pivoxil (CDTR-PI) to follow-up 1 month later. Serum L-carnitine and glucose
concentrations are shown. b CT scans of the femur acquired to assess skeletal muscle volume, which was markedly less than would be expected
in a healthy child
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